Key facts
- Ad Scientiam’s last known valuation is $6.3M (Nov 2025).
- It has raised $3.0M; the latest was PE Growth/Expansion ($1.6M) in Nov 2025.
- Notable investors include Bpifrance, EIT Health, Startup42, Techlife Capital, UW CoMotion — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Ad Scientiam
- ·The full record, as it builds
Funding rounds
No funding rounds for Ad Scientiam are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ad Scientiam
Developer of digital biomarker solutions intended for continuous disease monitoring. The company's platform captures real-world physiological and behavioral data via mobile devices and transforms it through proprietary algorithms, enabling healthcare professionals to personalize patient care and accelerate therapeutic development.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2013
- Employees
- 50
- Website
- adscientiam.com/
- Ownership
- Privately Held (backing)
Ad Scientiam doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ad Scientiam shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ad Scientiam in its N-PORT filings yet. We sweep new filings monthly.